Infliximab is the Conventional Trick for Ulcerative Colitis as a Novel Therapeutic Option Against SARS-CoV-2 Infection
| Author | Masoud Keikha | en |
| Orcid | Masoud Keikha [0000-0003-1208-8479] | en |
| Issued Date | 2020-10-20 | en |
| Abstract | This article does not have an abstract. | en |
| DOI | https://doi.org/10.5812/iji.108502 | en |
| URI | https://brieflands.com/journals/iji/articles/108502 | en |
| Keyword | Infliximab | en |
| Keyword | COVID-19 | en |
| Keyword | SARS-CoV-2 | en |
| Publisher | Brieflands | en |
| Title | Infliximab is the Conventional Trick for Ulcerative Colitis as a Novel Therapeutic Option Against SARS-CoV-2 Infection | en |
| Type | Letter | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- iji-7-4-108502.pdf
- Size:
- 82.13 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF